RLY-4008
Relay Therapeutics
[]
a new data cut showed promising response rates to 's selective fgfr2 inhibitor in a phase i/ii study to treat choloangiocarcinoma, suggesting its path to accelerated approval could be relatively short #esmo 
The leading voice for decision-makers throughout the global biopharma ecosystem. 
Free weekly podcast "BioCentury This Week": https://t.co/6CfHh0mIT6